Physicians face a significant problem in treating head and neck cancer since affectivity and therapy options differ from patient to patient and tumour site. Surgical treatments for head and neck cancers are limited due to the complexity of face tissues and functions, with surgery being the primary means of treatment. Functions including chewing, talking, and swallowing may be impacted after surgery. For the treatment of the disease, doctors use surgical surgery in conjunction with radiation therapy. In the last ten years, the survival rate of head and neck cancer has dropped from 80% to 50%, owing to existing treatment choices that mostly manage the symptoms. Recent advancements in sophisticated chemotherapy and radiotherapy have allowed some facial functions to be preserved. Targeted molecular therapy, such as gene therapy, monoclonal antibodies, and antibody drug conjugates, has opened up new growth opportunities for the head and neck cancer industry.
Read More:
https://bloggerstrive.blogspot.com/2022/03/head-and-neck-cancer-market-overview.html
Click here for Head and Neck Cancer Market Report:
https://www.coherentmarketinsights.com/market-insight/head-and-neck-cancer-market-530
